NEW YORK (GenomeWeb News) – Diagnostics company TheraGenetics will conduct a pharmacogenetic study along with King’s College London of Alzheimer’s patients who have been treated with cholinesterase inhibitors in the larger AddNeuroMed study.
 
TheraGenetics has been searching for genetic markers related to central nervous system disorders that could be used to develop diagnostic tests for Alzheimer’s disease, schizophrenia, depression, bipolar disorder, and attention deficit hyperactivity disorder.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.